Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study

Multiple Sclerosis Journal

Volumn 20, Issue 14, 2014, Pages 1900-1903

  Mancuso, R ^a   Franciotta, D ^b   Rovaris, M ^a   Caputo, D ^a   Sala, A ^a   Hernis, A ^a   Agostini, S ^a   Calvo, M G ^a   Clerici, M ^a  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Cerebrospinal fluid; intrathecal IgG; multiple sclerosis; natalizumab; oligoclonal bands

Indexed keywords

IMMUNOGLOBULIN G; NATALIZUMAB; OLIGOCLONAL BAND; POLYCLONAL ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; QUANTITATIVE ANALYSIS; CONTROLLED STUDY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; TREATMENT DURATION; BRAIN; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; OLIGOCLONAL BANDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84914182307     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514538111     Document Type: Article

References (12)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?. Arch Neurol. 2010 ; 67: 923-930
3. Von Glehn F, Farias AS, De Oliveira AC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012 ; 18: 1038-1041
4. Harrer A, Tumani H, Niendorf S, et al. Cerebrospinal fluid parameters of B-cell related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013 ; 19: 1209-1212
5. Tumani H, Deisenhammer F, Giovannoni G, et al. Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Ann Neurol. 2011 ; 70: 520
6. Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: Long-term results. Bone Marrow Transpl. 2012 ; 47: 946-951
7. Andersson M, Alvarez-Cermeno J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry. 1994 ; 57: 897-902
8. Reiber H.. Cerebrospinal fluid: Physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998 ; 4: 99-107
9. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol. 2008 ; 7: 852-858
10. Hiepe F, Dorner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011 ; 7: 170-178
11. Selter RC, Biberacher V, Grummel V, et al. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler. 2013 ; 19: 1454-1461
12. Villar LM, Garcia-Sanchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012 ; 69: 191-197